The trial aims to determine the comparative increase in lithium levels within the brain and its structures between Alzheimer’s patients and healthy subjects. Credit: Steven HWG on Unsplash.

Alzamend Neuro has announced a partnership with Massachusetts General Hospital (Mass General) to conduct a Phase II clinical trial of its lithium therapeutic drug candidate, AL001, to treat patients with Alzheimer’s disease.

The trial will also include a cohort of healthy subjects to compare plasma and brain pharmacokinetics.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Massachusetts General Hospital, affiliated with Harvard Medical School, will act as the contract research organisation for the study.

The trial aims to determine the comparative increase in lithium levels within the brain and its structures between Alzheimer’s patients and healthy subjects.

By analysing lithium content in patients’ brains during treatment, Alzamend aims to identify the minimum effective dose of AL001.

The company believes this study will support regulatory safety standards through the Section 505(b)(2) pathway for the US Food and Drug Administration (FDA) approval.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alzamend has already completed a Phase IIA clinical trial, establishing a maximum tolerated dose for AL001.

This dose, equivalent to 240mg of lithium carbonate taken three times daily, is designed to be safe for fragile populations without requiring therapeutic drug monitoring.

Alzamend CEO Stephan Jackman said: “We are elated to partner with Mass General and Dr Andronesi in this pivotal study for our lead therapeutic candidate AL001.

“If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require TDM, it would constitute a major improvement over current lithium-based treatments and positively impact the over six million Americans afflicted with Alzheimer’s. We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”